Biogen Inc.'s Form 4 filing
Sangamo Therapeutics, Inc (SGMOQ) · filed Sep 28, 2023
- Accession no.
- 0000899243-23-019611
- Filed
- Sep 28, 2023, 5:30 PM ET
- Trade date
- Sep 26, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $3.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biogen Inc.CIK 0000875045 | 10% Owner |
| Biogen MA Inc.CIK 0001810387 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 26, 2023 | Common Stock | SSaleDisposed | −6,000,000 | $0.50 | −$3,000,000 | 17,652,466 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.